Dr. Bill O’Neill: New Data from NCSI & Improving Outcomes in Cardiogenic Shock
“This is a coalition of the willing…I think all of you have to decide tomorrow when you go home, in your hospit...
Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care
Reference: J Am Coll Cardiol 2...
The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial
Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses...
National Cardiogenic Shock Initiative: 1 Year Later
Video Chapters:The Impact of The Cardiogenic Shock Initiative (NCSI):...
Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device
Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...
How to Better Evaluate, Identify and Manage Shock Patients
Recently, Abiomed’s platform of Impella® heart pumps received FDA approval for the treatment of patients experiencing cardio...
The FDA’s Shock Indication for the Impella
The FDA recently granted Abiomed approval to expand Impella™ 2.5 PMA to treat patients suffering cardiogenic shock follo...
Significance of FDA Approval of Impella for Cardiogenic Shock
Listen to Dr. William W. O’Neill, Medical Director for the Center for Structural Heart Disease at Henry Ford Hospital, discus...
